Nalgoova Therapeutics is a Swiss healthtech company developing a novel, targeted approach to the treatment of severe migraines. Despite affecting millions of patients worldwide, migraines are still largely managed with generalized therapies that often provide limited relief and can lead to significant side effects.
Nalgoova is building an integrated solution that enables clinicians to identify and treat pain in a more precise and personalized way. By combining proprietary technology with a new clinical workflow, the company aims to significantly reduce pain intensity, frequency of attacks, and reliance on medication. Early results indicate meaningful clinical impact across severe migraine conditions.
Nalgoova’s vision is to transform migraine care from generalized symptom management to precise, patient-specific treatment.
